Why access-first thinking is reshaping the future of pharma commercialisation
Market access used to be something you figured out near the end of the commercialisation process. You’d line up your commercial plan, get close to launch, and then ask, ‘Have we sorted access yet?’ But in 2025, that approach no longer holds up. The companies making real progress are the ones building market access into their strategies from the very beginning.
When you integrate pharma market access early in the planning process, everything becomes more connected: your clinical plans, pricing strategies, and evidence generation all align with what matters most. And when that happens, launches feel smoother, and the impact is bigger. If you’re looking to enhance your strategy, it’s worth taking a step back and looking at the bigger picture. In working with pharma teams across different therapy areas and markets, we’ve seen the biggest gains come from shifting from siloed planning towards a more connected approach to market access.
That’s where a simple framework can help. Below are seven focus areas I’ve seen consistently improve pharma market access strategies. You don’t need to hit all of them at once. The goal is to build alignment across the ones that matter most to your team right now, and grow from there.
The framework for stronger pharma market access
- Focus on value people actually care about
While robust clinical data remains critical, it no longer guarantees market access. What sets successful pharma market access strategies apart today is the ability to clearly demonstrate real-world value with stories that focus on meaningful outcomes and the broader impact on healthcare systems.
The strongest narratives don’t come together at the last minute. They’re shaped early, with endpoints that reflect what payers and providers actually want to see. Testing those messages before the final data is in gives teams a huge head start, and results in a story that resonates.
- Bring people in early and often
Integrating market access into early-stage planning helps avoid last-minute trade-offs and sets the foundation for smarter execution. That means bringing access professionals into early discussions, right alongside commercial, medical, regulatory, and clinical teams.
This kind of cross-functional collaboration leads to sharper trial designs, more relevant evidence plans, and fewer surprises as you approach launch. According to CapSys Group’s Re-thinking Market Access report (2023), early and multi-stakeholder engagement is a defining trait of successful market access strategies. The companies that do this well build strong internal and external relationships that break down barriers and drive better outcomes.
- Make pricing part of the bigger picture
Pricing is one of the first things payers look at, so it shouldn’t be one of the last things you plan. Getting strategic early, with payer insights, value modelling, and scenario planning, gives teams more options and more credibility.
Value-based pricing and outcomes-based agreements are becoming standard practice in many markets. Developing a pricing strategy from the outset allows you to stay ahead of the competition and position your product more effectively.
- Plan for local realities from the beginning
Even the most polished global strategy can fall short if it doesn’t account for local dynamics. Reimbursement rules, health technology assessments, and payer expectations vary, sometimes dramatically, between countries and even within them.
That’s why the most effective teams tap into local expertise early, building tailored strategies that reflect regional priorities and realities. This kind of flexibility supports stronger launches and helps avoid costly missteps. As noted by PwC’s Strategy& (2021) in recent analysis, the decentralisation of healthcare systems across many markets is making localised approaches more critical than ever to commercial success.
- Put digital at the centre
Digital tools have become indispensable in modern pharma market access strategies. They play a crucial role in enhancing patient experience and demonstrating product value to payers.
These tools go beyond simple data collection, supporting patient adherence, monitoring outcomes in real time, and helping reduce strain on healthcare systems. In 2025, digital integration is a core component of any successful pharma commercialisation strategy. Integrating digital solutions early enables pharma companies to build more compelling value propositions that resonate with both patients and payers.
- Treat real-world evidence as a long-term investment
Real-world evidence (RWE) is now a fundamental part of sustaining and expanding pharma market access throughout a product’s lifecycle, not just after launch. Leading companies use RWE to support label extensions, inform pricing negotiations, and drive ongoing lifecycle management. This type of evidence keeps products both clinically relevant and commercially competitive. Integrating RWE into your strategy early will make you better equipped to adapt to evolving market needs and sustain long-term success.
- Keep your focus on what truly matters
Successful pharma commercialisation starts with a clear focus on what really matters to patients, payers, and regulators. Teams that align on these core priorities are more efficient, make quicker decisions, and achieve better outcomes. In pharma market access, this alignment, both internally and externally, drives tangible, measurable success.
Final thoughts: Start early and build around access
The best teams have moved past static timelines and one-size-fits-all planning in the drug commercialisation process. Rather than approaching each stage in isolation, they’re building responsive, connected plans that can adapt to market shifts and external pressures.
There’s no single blueprint for pharma commercialisation, but the most successful companies provide a clear path forward. They bring market access into the conversation early, foster collaboration across teams, and stay closely aligned with what patients and payers really need.
If you’re already putting some of these strategies into practice, great! Keep building on them. If you’re just starting out, choose one focus area that makes sense for your team and dive deeper. The key takeaway remains the same: the strongest pharma market access strategies are integrated from the very beginning.
Prioritising market access from day one helps set the stage for a product launch that delivers lasting impact, creating value not just at launch, but throughout the product’s lifecycle for patients, payers, and your business.
Contact us
